

Jew 1624

PATENT Attorney Docket No. UDL-003C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Darrow et al.

CONFIRMATION NO.:

8430

SERIAL NO.:

10/083,245

GROUP NO.:

1624

FILING DATE:

February 25, 2002

EXAMINER:

Not yet assigned

TITLE:

CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO

[1,5-a]-1,3,5-TRIAZINES

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this and day of July, 2004.

Lisa Marie Solis

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith are:

- 1. Transmittal Form (1 page);
- 2. Supplemental Information Disclosure Statement (3 pages); and
- 3. Form PTO-1449 (1 page);
- 4. Copy of cited references A1-A7 and B1-B5; and
- 5. A Return Receipt Postcard.

3089132-1

TPS (
200			Application Serial Number			10/083,245			
JUL	0 7 2004 [2]	Filing Date			February 25, 2002				
			First Name	d Inventor		Darrow			
NSMITTAL			Group Art Unit			1624			
			Examiner N	lame		Not yet assigned			
FORM			Attorney Docket No.			UDL-003C1			
			Patent No.			Not yet assigned			
			Issue Date			Not yet assigned			
ENCLOSURES (check all that apply)									
☐ Fee	Transmittal Form	□ ?	Copy of Notice Parts of Appli	e to File Missing cation		Notice of Appeal to Board of Patent Appeals and Interferences			
	☐ Check Attached☐ Copy of Fee Transmittal Form		Formal Drawi	ng(s)		Appeal Brief (in triplicate)			
	Amendment/Response		Request For C Examination (Transmittal			Status Inquiry			
	☐ After Final				Ø	Return Receipt Postcard			
	Affidavits/declaration(s) Letter to Official Draftsperson		Power of Atto (Revocation o	rney f Prior Powers)	×	Certificate of First Class Mailing under 37 C.F.R. 1.8			
	including Drawings [Total Sheets]		Terminal Disclaimer			Certificate of Facsimile Transmission under 37 C.F.R. 1.8			
	Petition for Extension of Time			r Utility or Design		Additional Enclosure(s) (please identify below)			
⊠	Supplemental Information Disclosure Statement		Small Entity Statement						
	✓ Form PTO-1449✓ Copies of IDSCitations A1-A7 andB1-B5		CD(s) for large table or computer program						
	Certified Copy of Priority Document(s)		Amendment A	After Allowance					
	Sequence Listing submission Paper Copy/CD Computer Readable Copy Statement verifying identity of above	Request for Certificate of Correction Certificate of Correction (in duplicate)							
CORRE	ESPONDENCE ADDRESS			SIGNATURE BLOCK					
Direct all correspondence to: Patent Administrator Testa, Hurwitz & Thibea High Street Tower 125 High Street Boston, MA 02110 Tel. No.: (617) 248-7100 Fax No.: (617) 248-7100			ibeault, LLP	Date: July Z , 2004 Reg. No. 45,508 Tel. No.: (617) 248- Fax No.: (617) 248-	-722				



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Darrow et al.

CONFIRMATION NO.:

8430

SERIAL NO:

10/083,245

GROUP NO.:

1624

FILING DATE:

February 25, 2002

EXAMINER:

Not yet assigned

TITLE:

CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO

[1,5-a]-1,3,5-TRIAZINES

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

In addition, Applicants wish to inform the Examiner about the following patents and patent applications, and the contents of their file wrappers, including all Office actions issued therein.

- 1) U.S.S.N. 09/676,970, entitled "Certain Alkylene Diamine-Substituted Pyrazolo [1,5-a]-1,3,5-Triazines," filed on September 29, 2000, and issued on April 16, 2002, as U.S. Patent No. 6,372,743 B1 (Reference A1).
- 2) U.S.S.N. 09/676,941, entitled "Certain Alkylene Diamine-Substituted Heterocycles," filed on September 29, 2000, and issued on January 14, 2003, as U.S. Patent No. 6,506,762 B1 (Reference A2).
- 3) U.S.S.N. 10/291,446, entitled "Certain Alkylene Diamine-Substituted Heterocycles," filed on November 8, 2002, and issued on February 24, 2004, as U.S. Patent No. 6,696,445 B2 (Reference A4).
- 4) U.S.S.N. 10/705,446, entitled "Certain Alkylene Diamine-Substituted Heterocycles," filed on November 10, 2003.

- 5) U.S.S.N. 10/274,851, entitled "Substituted 2-Cyclohexyl-4-Phenyl-1H-Imidazole Derivatives," filed on October 21, 2002, and published on July 31, 2003, as U.S. Application Publication No. 2003/0144290 (Reference A6).
- 6) U.S.S.N. 10/415,457, entitled "Spiro[Isobenzofuran-1,4'-Piperidin]-3-Ones and 3H-Spiroisobenzofuran-1,4'-Piperidines," filed on April 29, 2003.
- 7) U.S.S.N. 09/771,956, entitled "Chimeric Neuropeptide Y Receptors," filed on January 29, 2001, and published on October 18, 2001, as U.S. Application Publication No. 2001/0031474 (Reference A5).
- 8) U.S.S.N. 10/013,846, entitled "Spiro[Isobenzofuran-1,4'-Piperidin]-3-Ones and 3H-Spiroisobenzofuran-1,4'-Piperidines," filed on December 11, 2001, and issued on May 20, 2003, as U.S. Patent No. 6,566,367 B2 (Reference A3).
- 9) U.S.S.N. 10/410,648, entitled "Spiro[Isobenzofuran-1,4'-Piperidin]-3-Ones and 3H-Spiroisobenzofuran-1,4'-Piperidines," filed on April 9, 2003, and published on April 15, 2004, as U.S. Application Publication No. 2004/0072847 (Reference A7).

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

(1)	within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
(2)	after the period defined in (1) but before the mailing date of a final action or a notice of allowance under 37 C.F.R. 1.311, and
	the requisite Statement is below, OR
	the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or
(3)	after the mailing date of a final action or notice of allowance but before the payment of the issue fee, AND
	the requisite Statement is below, AND

Supplemental Information Disclosure Statement Serial No. 10/083,245 Page 3 of 3

the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- 1. Each item of information contained in the Information Disclosure
 Statement was first cited in any communication from a foreign patent
 office in a counterpart foreign application not more than three months
 prior to the filing of the Information Disclosure Statement; or
- No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Date: July 2, 2004 Reg. No. 45,508

Tel. No.: (617) 248-7226 Fax No.: (617) 248-7100

3081840

Respectfully submitted,

Daniel A. Wilson

Attorney for the Applicants Testa, Hurwitz & Thibeault, LLP

High Street Tower 125 High Street

Boston, Massachusetts 02110



EMARIT													
FORM PTO - 1449					A	ATTORNEY DOCKET NO.: UDL-003C1 APPLICANT(S): Darrow et al. SERIAL NO.: 10/083,245							
SUPPLEMENTAL INFORMATION				A									
DISCLOSURE STATEMENT					S								
							FILING DATE: February 25, 2002 GROUP: 1624						
			U.S.	PATI	ENT D	OCUME	NTS						
EXAM. INIT.					NAME		CLASS	SUB CLASS	FILING DATE IF APPROPRIATE				
	A1	6,372,743 B1	04/16/200	2	Darrow	et al.				09/29/2000			
	A3 6,566,367 B2 05/20/2003 Ba A4 6,696,445 B2 02/24/2004 Ho		Horvath	vath et al.			09/29/2000		2/2000				
			3	Bakthavatchalam et al.					12/11/2001				
			4	4 Horvath et al.				11/08	11/08/2002				
			10/18/200	8/2001 Kin		ade et al				01/29/2001 10/21/2002			
	A6 2003/0144290 A1 07/31/2003 A7 2004/0072847 A1 04/15/2004			3	Blum et								
,, ,,				4	Bakthavatchalam et al.				04/09/2003		2/2003		
		<u> </u>	FOREIG	GN PA	ATENT	DOCUN	MENTS						
EXAM. INIT.		DOCUMENT NUMBER	DATE	COD	NTRY	CLASS	SUB CLASS	FILING DATE	ONLY		ENGLISH LANG (Y/N)		
	B1	WO 01/23387	04/05/2001	PCT PCT					N		Y		
	B2	WO 01/23389	04/05/2001						N		Y		
	В3	WO 01/55103	08/02/2001	PCT					N		Y		
	B4	WO 02/48152	06/20/2002	РСТ					N	-	Y		
	B5	WO 03/104255	12/18/2003	PCT					N		Y		
			OTHER AR	T, JO	URNA	L ARTIC	CLES, E	ETC.			1		
EXAM. INIT.	ТО	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)											
	T												

DATE CONSIDERED

EXAMINER